Fumaric acid esters have proved to be effective for the systemic treatment of severe psoriasis vulgaris. These compounds have been shown to induce a Th2-like cytokine secretion pattern in T cells and to reduce keratinocyte proliferation in vitro. Dendritic cells seem to be of major importance as regulatory cells driving the psoriatic tissue reaction. Monocytes or CD34-positive myeloid progenitor cells are precursors of dendritic cells that can be generated in vitro by culture with granulocyte-macrophage colony-stimulating factor and interleukin-4. Using this model the effect of fumaric acid esters on granulocyte-macrophage colony-stimulating factor/ interleukin-4-induced differentiation of monocytederived dendritic cells was investigated. The results of this study show that dimethylfumarate as well as methylhydrogenfumarate-calcium-salt (0.01±100 mg per ml) concentration-dependently inhibit monocytederived dendritic cell differentiation. This was re¯ected by an inhibition of CD1a, CD40, CD80, CD86, and HLA-DR expression as well as by a reduced capacity of dimethylfumarate-treated monocyte-derived dendritic cells to stimulate lymphocytes in the allogeneic mixed lymphocyte reaction. Other fumaric acid esters showed no effect on monocytederived dendritic cell-differentiation. At higher concentrations (30±100 mg per ml) dimethylfumarate, but not methylhydrogenfumarate calcium-salt induced apoptosis in monocyte-derived dendritic cells as measured by expression of Apo 2.7 and DNA fragmentation (TUNEL assay). These data point to a high susceptibility of the monocyte/dendritic cell system to dimethylfumarate and its main metabolite methylhydrogenfumarate. Other fumaric acid esters investigated were without effect. As the effects of fumarates on monocyte-derived dendritic cells observed occur at concentrations 20-fold lower compared with lymphocytes, our data seem to be of relevance in explaining the possible mode of action of these compounds in psoriasis.
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Evidence for a pharmacologic in¯uence of FAE on components of the immune system was ®rst provided by demonstrating an inhibition of lymphocyte proliferation by monoethylfumarate (Petres et al, 1975) . Recently, FAE were demonstrated to increase production of interleukins (IL)-4 and -5 without changing the production of IL-2 and interferon-g in stimulated peripheral blood mononuclear cells (De Jong et al, 1996) . In Th1/Th0 clones challenged with bacterial antigen-enhanced secretion of IL-4 and IL-5 could be induced by monomethylfumarate without affecting interferon-g secretion (De Jong et al, 1996) .
In human peripheral blood mononuclear cells, monomethylfumarate increased production of IL-10, IL-1 receptor antagonist, and tumor necrosis factor-a; however, the production of IL-12 was not affected (Asadullah et al, 1997) . Co-culture experiments using keratinocytes from psoriasis patients and healthy controls together with HUT78 T cells revealed inhibition of interferon-g secretion and induction of IL-10 by dimethylfumarate (DMF) (Ockenfels et al, 1998) .
These data indicate that FAE may skew the Th1-dominated immune response underlying the psoriatic tissue reaction towards a Th2-type response.
Dendritic antigen-presenting cells are increased in number in psoriatic lesions and are crucial in initiating a T cell mediated immune response (Nestle et al, 1994) . Furthermore, dendritic cells are able to direct T cell development into a Th1-or Th2-like pathway (Kalinski et al, 1999) .
We have investigated whether FAE may modulate dendritic cell differentiation and antigen-presenting activity. Our data provide evidence for a high susceptibility of dendritic cells to DMF and methylhydrogenfumarate (MHF) bene®cial effect of DMF as the major ingredient of the marketed drug and its main metabolite MHF in the treatment of psoriasis. Additional experiments performed in order to investigate the underlying mechanisms of this effect more closely point towards the induction of apoptosis in dendritic cells by DMF.
MATERIALS AND METHODS
Culture medium and reagents The standard medium for cell culture was RPMI 1640 (BioConcept, Umkirch, Germany) supplemented with 2 mM L-glutamine, 10% heat inactivated fetal bovine serum (BioConcept, Umkirch), 100 U penicillin per ml, 100 mg streptomycin per ml. For dendritic cell culture 100 U granulocyte-macrophage colony-stimulating factor (GM-CSF) per ml (Leucomax, Novartis Pharma, Nu Èrnberg, Germany) and 10 ng IL-4 per ml (kindly supplied by Schering-Plough, Kenilworth, NJ) was added to the supplemented medium.
Phycoerythrin-or¯uorescein isothiocyanate-conjugated monoclonal antibodies against the epitopes CD1a, CD14, CD40, CD80, CD86, and HLA-DR as well as their respective isotype controls were from CoulterImmunotech (Krefeld, Germany).
The following fumaric acid esters (Merck, Darmstadt, Germany) were used in this study: methylhydrogenfumarate (MHF), methylhydrogenfumarate calcium salt (Ca-MHF), ethylhydrogenfumarate magnesium salt, ethylhydrogenfumarate calcium salt, DMF, fumaric acid, monoethylfumarate, pentylhydrogenfumarate, and isopropylhydrogenfumarate. DMF was dissolved in dimethyl sulfoxide and later diluted with standard medium, the other FAE used were dissolved in standard medium. Dilutions of FAE were prepared freshly and sterilized by ®ltration through 0.2 mM pore-size membranes (Sartorius, Go Èttingen, Germany).
Except for DMF and Ca-MHF, FAE were used at a concentration of 10 mg per ml. DMF and Ca-MHF were employed at various concentrations ranging from 0.01 to 100 mg per ml. Standard medium and DMSO were equally tested as solvent control.
Generation of dendritic cells and cell culture Human puri®ed monocytes were isolated by counter¯ow centrifugation elutriation from peripheral blood mononuclear cells, obtained by Ficoll Paque (Biochrom, Berlin, Germany) density gradient centrifugation of ethylenediamine tetraacetic acid-anticoagulated venous blood from healthy donors after informed consent. Purity of monocytes was assessed by cell-size analysis (Coulter counter-channellyzer), and by microscopic evaluation of Giemsastained cytospin preparations.
Monocytes were cultured at a density of 1.5±2 Q 10 6 per ml in six-well at bottom tissue-culture plates (Becton-Dickinson, Heidelberg, Germany) at 37°C in a humidi®ed atmosphere with 5% CO 2 in standard medium together with GM-CSF and IL-4 to generate immature, in¯ammatory-type monocyte-derived dendritic cells (Sallusto and Lanzavecchia, 1994) . Monocytes were treated from the beginning with FAE or DMSO (®nal concentration 0.1%) or left with medium alone. Differentiation of dendritic cells was controlled daily using an inverted microscope.
Flow cytometric analysis GM-CSF/IL-4-induced differentiation of monocyte-derived dendritic cells and the effect of FAE on this process was assessed by single color¯ow cytometry. Analysis was performed using an EPICS-XL¯ow-cytometer and system II software (Coulter). Brie¯y, cells were harvested after 5 d of culture and resuspended in phosphate-buffered saline (PBS). Pelleted cells (5 Q 10 5 ) in 100 ml PBS were incubated for 30 min at room temperature in darkness with antibodies against CD1a, CD14, CD40, CD80, CD86, and HLA-DR as well as their corresponding phycoerythrin-labeled or¯uorescein isothiocyanate-labeled isotype control antibodies to determine the level of background staining. At least 1 Q 10 4 viable monocyte-derived dendritic cells per sample, gated according to forward and side scatter characteristics, were analyzed.
Allogeneic mixed lymphocyte reaction (MLR) MLR was performed using puri®ed allogeneic T cells as responder cells and monocyte-derived dendritic cells as stimulator cells. Puri®ed T cells were obtained by negative selection using the MACS-system (Miltenyi Biotech, Bergisch Gladbach, Germany) employing monoclonal antibodies coupled to magnetic beads against the following epitopes: CD11b, CD16, CD19, CD36, and CD56. Brie¯y, 2 Q 10 4 monocyte-derived dendritic cells after 5 d of culture in the presence of DMF (1.0 and 10 mg per ml) or DMSO (0.01%, vol/vol) as solvent control were mixed with 5 Q 10 4 responder cells in a ®nal volume of 200 ml RPMI 1640 supplemented with 10% heatinactivated human AB serum, 2 mM L-glutamine, 100 U penicillin per ml, 100 mg streptomycin per ml and 10 mM HEPES in 96-well roundbottomed microtiter plates (Costar, Bodenheim, Germany) at 37°C in a humidi®ed atmosphere with 5% CO 2 for 5 d. Three different monocytederived dendritic cells/T cell ratios were investigated: 1:1, 1:10, and 1:100. Proliferation of lymphocytes was assessed after addition of 1 mCi per well [ 3 H]thymidine (speci®c activity: 5 Ci per mmol; Amersham, Braunschweig, Germany) for the last 24 h of culture. Cells were harvested on glass ®ber with a semiautomated cell harvester apparatus (Skatron, Vienna, Austria) and [ 3 H]thymidine incorporation was measured in a liquid scintillation spectrometer (Beckman, Munich, Germany). All experiments were performed in triplicate and expressed as mean counts per minute (cpm) T SD.
Determination of apoptosis by¯ow cytometry Flow cytometry was used for detecting the cells undergoing apoptosis. Monocyte-derived dendritic cells after 5 d of culture in the presence of DMSO or FAE were harvested and washed twice with PBS. Then, 1 Q 10 6 cells suspended in 100 ml of PBS were incubated for 30 min at room temperature in darkness with a monoclonal antibody against Apo 2.7 (Coulter-Immunotech). To exclude nonspeci®c staining, cells stained with corresponding isotypematched monoclonal antibodies were used as controls. For each sample, a minimum of 10,000 cells, gated according to the forward and side scatter characteristics, were analyzed.
Determination of apoptosis by the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) method In order to verify apoptotic mechanisms induced in monocyte-derived dendritic cells by FAE a second independent method was used. TUNEL of nucleosomal DNA fragments with the commercially available``In Situ Cell Death Detection Kit'' (Boehringer Mannheim, Mannheim, Germany) was employed according to the manufacturer's protocol. This method was used to ensure a safe discrimination between apoptosis and necrosis.
Statistical analysis Statistical analysis was performed from the data obtained using the unpaired Student's t test. A p < 0.05 was considered signi®cant.
RESULTS
Viability and purity of monocytes and monocyte-derived dendritic cells Human monocytes showed a purity of greater than 95% and a viability of > 98% after elutriation. After 5 d of culture with GM-CSF/IL-4 the viability of monocyte-derived dendritic cells was greater than 90% as judged by Trypan blue exclusion.
Treatment of cells with FAE (up to 10 mg per ml) or DMSO (0.01%, vol/vol) did not alter viability of monocyte-derived dendritic cells. Using FAE in concentrations exceeding 50 mg per ml monocyte-derived dendritic cells showed morphologic changes (increased granularity, reduced dendrites) and viability was decreased to about 75%.
Effect of FAE on the differentiation of monocyte-derived dendritic cells Differentiation of monocyte-derived dendritic cells by culturing monocytes for 5 d in standard medium with GM-CSF/IL-4 was analyzed by¯ow cytometry using monoclonal antibodies against CD1a, CD14, CD40, CD80, CD86, and HLA-DR. The results shown in Fig 1 demonstrate the typical CD1a/ CD40 (high), CD14 (low) monocyte-derived dendritic cells phenotype as compared with monocytes. CD80, CD86, and HLA-DR were also expressed on monocyte-derived dendritic cells.
Treatment of monocytes with DMF (10 mg per ml), (Fig 1A) a concentration not inducing signi®cant apoptosis (see below and Fig 3) lead to a signi®cant decrease in cells expressing CD1a, CD40, CD86, and HLA-DR. There was no change in CD14 expression by DMF. DMSO (0.01%, vol/vol) corresponding to a FAE concentration of 10 mg per ml had no effect on the differentiation of monocyte-derived dendritic cells. Figure 1(B) demonstrate the effect of Ca-MHF (100 mg per ml) on MoDC differentiation. The substance reduced expression of CD1a, CD40, CD80, CD86, and HLA-DR signi®cantly. Interestingly, CD14-expression was upregulated by Ca-MHF at this concentration, indicating a pronounced shift of the cells to a monocyte/ macrophage phenotype. Furthermore, all other FAE investigated as well as fumaric acid had no effect on monocyte-derived dendritic cells differentiation (data not shown).
Concentration-dependent inhibitory effect of DMF and
Ca-MHF on the differentiation of monocyte-derived dendritic cells We next analyzed if the effect of DMF on monocyte-derived dendritic cells differentiation was concentration related. For comparison, the main DMF metabolite MHF in the form of calcium salt was tested equally. Figure 2 demonstrates concentration-dependent effects of DMF and Ca-MHF (0.01±100 mg per ml) on CD1a, CD14 expression and HLA-DR expression. A signi®cant inhibition of CD1a expression was found for DMF at a concentration of 10 mg per ml (p < 0.01) and 100 mg per ml (p < 0.001), respectively. Expression of HLA-DR was signi®cantly reduced at all concentrations used (p < 0.05).
Ca-MHF signi®cantly inhibited CD1a-expression at 1 and 10 mg per ml (p < 0.05) and 100 mg per ml (p < 0.001), respectively. At a concentration of 10 and 100 mg per ml expression of HLA-DR was also reduced (p < 0.05). Ca-MHF, but not DMF, signi®cantly upregulated CD14 at 100 mg per ml (p < 0.05).
DMF inhibit the antigen-presenting function of monocytederived dendritic cells Monocyte-derived dendritic cells function as potent antigen-presenting cells and possess a high capacity to stimulate lymphocytes in the MLR. As phenotypic analysis showed that DMF inhibits differentiation (CD1a/CD40Ð low) we analyzed the stimulatory capacity of DMF-treated monocyte-derived dendritic cells in allogeneic MLR.
In comparison with solvent (DMSO) -treated control cells [ 3 H]thymidine uptake of puri®ed allogeneic T cells was decreased in a concentration-dependent fashion after incubation with DMFtreated monocyte-derived dendritic cells ( Table I) . Inhibition of DMF-induced [ 3 H]thymidine uptake was most pronounced using monocyte-derived dendritic cells/T cell ratios of 1:1 and 1:10 in comparison with the solvent control.
Induction of apoptosis by FAE As DMF and Ca-MHF in concentrations above 50 mg per ml caused increased granularity, reduced dendrites and decreased viability we asked whether these morphologic alterations could be due to the induction of apoptosis. To ensure a safe detection of apoptotic processes two independent assay systems were employed. As shown in Fig 3(A) DMF not Ca-MHF, however, induced a concentration-dependent increase in the number of apoptotic cells as determined by Apo 2.7 expression. At the highest concentration of DMF used (100 mg per ml) more than 90% of monocyte-derived dendritic cells stained positive for Apo 2.7 indicating induction of apoptosis.
Using TUNEL as a second method to detect apoptosis DMF was shown to induce DNA fragmentation in a concentrationdependent manner (Fig 3B) . At 100 mg per ml DMF about 80% of monocyte-derived dendritic cells were demonstrated to be apoptotic by terminal deoxynucleotidyl transferase labeling. Ca-MHF-treated monocyte-derived dendritic cells showed no terminal deoxynucleotidyl transferase labeling, indicating DNA integrity.
DISCUSSION
Fumaric acid esters have been found to be effective in the treatment of psoriasis by empiric means (Schweckendiek, 1959) . Meanwhile, fumarates have successfully been used for more than 40 y, mainly in Germany and in the Netherlands as a de®ned mixture of different FAE, with DMF being the major compound. DMF is rapidly hydrolyzed into MHF (also called monomethylfumarate), which is regarded to be a major active metabolite. On the basis of the chemical properties of DMF, this compound may penetrate cellular membranes more easily as compared with Ca-MHF or MHF.
Several studies have been conducted to elucidate the mechanism of action of FAE in the treatment of psoriasis and the results of these investigations have been summarized recently (Mrowietz et al, 1999) . MHF has been shown to stimulate tumor necrosis factor-a, IL-10, and IL-1 receptor antagonist production in human peripheral blood mononuclear cells without an effect on IL-12 secretion (Asadullah et al, 1997) . Besides an antiproliferative effect on keratinocytes (Sebo Èk et al, 1994) and lymphocytes (Petres et al, 1975) in vitro, cells of the monocytic lineage seem to be an additional important target for the action of FAE.
The results of our study show that DMF and its main in vivo metabolite MHF as investigated by the use of its calcium-salt is able to interfere with the differentiation of dendritic cells from monocytes in vitro. DMF and MHF inhibited upregulation of the dendritic cell marker CD1a, the costimulatory molecules CD80 and CD86, CD40 and of the major histocompatibility complex class II molecule HLA-DR. Most profound changes were observed for CD1a and CD40 (Fig 1) . DMF and Ca-MHF showed concentration-dependent effects up to the highest concentration of 100 mg per ml used. The phenotypical changes induced in FAEtreated monocyte-derived dendritic cells were re¯ected functionally by an inhibition of antigen-presenting function by DMF as analyzed in the MLR.
As compared with other in vitro effects of FAE, such as the induction of IL-4/IL-5 in MHF-treated T cells, the effect of DMF and Ca-MHF on monocyte-derived dendritic cells differentiation was observed at a 20±200 times lower concentration (Mrowietz et al, 1999) .
To address the question if changes in cellular morphology observed at higher concentrations of FAE (> 50 mg per ml) may be due to the induction of apoptosis, we performed additional experiments with DMF and Ca-MHF in concentrations up to 100 mg per ml. Apoptosis was measured by two independent methods. The expression of the marker Apo 2.7 is a sensitive measure to detect induction of apoptosis at an early stage (Zhang et al, 1996) . The TUNEL technique demonstrates DNA fragmentation (Loo and Rillema, 1998) . Using both methods it could be shown that DMF concentration-dependently induced apoptosis in monocyte-derived dendritic cells, whereas Ca-MHF had no effect (Fig 3) . From these results it may be concluded, that the inhibition of monocyte differentiation by DMF at higher concentrations may be due to the induction of apoptosis.
Dendritic cells are regarded to play a crucial part in the pathogenesis of psoriasis. These cells are increased in number in lesional skin and show enhanced immunologic activity (Nestle et al, 1993 (Nestle et al, , 1994 . In the light of recent evidence that psoriasis may be caused by (auto)antigen(s) dendritic antigen-presenting cells will drive the pathogenetic process (Valdimarsson et al, 1997; Drakesmith et al, 2000) . Therefore, targeting the dendritic cell system seems to be an effective measure to treat psoriasis. As dendritic cells do not proliferate in situ, precursors such as monocytes or CD34 + myeloid progenitor cells are recruited from the peripheral blood differentiating in the tissue into immunologically active cells (Muller and Randolph, 1999) . GM-CSF/IL-4-induced monocyte-derived dendritic cells represent so-called immature dendritic cells, which home at sites of in¯ammation as recently demonstrated (Barratt-Boyes et al, 1998) . Inhibition of monocyte-derived dendritic cell differentiation, therefore, may lead to cells with a decreased immunologic activity as we have shown in this study.
Recently, IL-10 was found to have bene®cial effects in patients with severe psoriasis (Asadullah et al, 1998; Reich et al, 1998) . As demonstrated earlier IL-10 inhibited GM-CSF/IL-13-induced differentiation of human monocytes into monocyte-derived dendritic cells (Allavena et al, 1998) . A reduction of CD1a expression and an upregulation of CD14 as well as a reduced ability of monocyte-derived dendritic cells to stimulate allogeneic T cells in the MLR was found after IL-10 treatment. Further analysis revealed, that IL-10 shifted GM-CSF/IL-13-induced dendritic cell development towards a macrophage-like differentiation. Very recently 1,25-dihydroxycholecalciferol, the active metabolite of vitamin D 3 , was found to inhibit monocyte-derived dendritic cell differentiation and T cell-stimulating capacity in the MLR (Penna and Adorini, 2000; Piemonti et al, 2000) . This, however, was not described to be due to the induction of apoptosis.
The loss of antigen-presenting activity of monocyte-derived dendritic cells as shown by the decreased ability to stimulate the MLR after DMF treatment led to a decreased immunologic activity. The inhibition of CD40 expression and the downregulation of CD80/CD86 may be directly linked to this effect (Grewal and Flavell, 1998; van Kooten and Banchereau, 2000) . As this is achieved at a 20-fold lower concentration as compared with other in vitro effects of FAE, such as the induction of IL-4 and IL-5 in Th1/Th0-clones, it may be of relevance in vivo. At higher concentrations DMF seems to alter monocyte-derived dendritic cells by inducing apoptosis. The induction of apoptosis as a possible mechanism of action has been described for methotrexate (Genestier et al, 1998) and ultraviolet light (Ozawa et al, 1999) , both regimens being effective in the treatment of psoriasis. Very recently, DMF not other FAE, however, was found to induce apoptosis in the lymphohistiocytic cell line U937 in a concentration range of 30±100 mmol per liter (Sebo Èk et al, 2000) . These data fully support the ®ndings observed in this study. The induction of apoptosis in target cells by DMF in higher concentrations seems to be a unique feature for this fumaric ester, as Ca-MHF and other FAE at these concentrations did not induce apoptosis. Further investigations are needed in order to de®ne more closely the effects of FAE observed in this study with regard to the clinically proven effectiveness of the compounds in the treatment of severe psoriasis. 
